[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351851-105":59,"doc-detail-351851-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","formulation-characterization-and-evaluation-of-cytotoxic-potential-for-febuxostat-loaded-chitosomes-against-cervical-cancer-cells-hela-cells","Formulation, characterization and evaluation of cytotoxic potential for febuxostat loaded chitosomes against cervical cancer cells (Hela cells)","","Study evaluates repurposing Febuxostat (FBX) as a chemotherapeutic agent against cervical cancer cell line Hela. FBX is incorporated into chitosan-coated niosomes (chitosomes) to exploit nanotechnology advantages in drug delivery. A 23 factorial design characterizes eight formulations for entrapment efficiency, particle size, and zeta potential. Optimized FBX-loaded chitosomes show 339 ± 14 nm size, 91.07 ± 0.33% entrapment, and +26.9 ± 1.2 mV zeta potential. In vitro assays demonstrate a ~3-fold IC50 reduction versus free FBX, doubled cellular uptake, and G1/S apoptotic cell death, indicating strong cytotoxicity and biocompatibility.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/formulation-characterization-and-evaluation-of-cytotoxic-potential-for-febuxostat-loaded-chitosomes-against-cervical-cancer-cells-hela-cells/351851/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/formulation-characterization-and-evaluation-of-cytotoxic-potential-for-febuxostat-loaded-chitosomes-against-cervical-cancer-cells-hela-cells/351851.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"How are febuxostat-loaded chitosomes prepared and optimized?","Question",{"text":113,"@type":114},"FBX is incorporated into chitosan-coated niosomes (chitosomes). A 23 factorial design evaluates multiple formulations based on entrapment efficiency, particle size, and zeta potential to identify an optimized dispersion.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What physicochemical results are reported for the optimum formulation?",{"text":118,"@type":114},"The optimized FBX-loaded chitosomes show a mean particle size of 339 ± 14 nm, entrapment efficiency of 91.07 ± 0.33%, and a zeta potential around +26.9 ± 1.2 mV.",{"name":120,"@type":111,"acceptedAnswer":121},"How does the formulation affect cytotoxicity against Hela cells compared with free FBX?",{"text":122,"@type":114},"In vitro studies show a significant ~3-fold decrease in IC50 compared with pure FBX, and cellular uptake increases about 2-fold relative to the free drug.",{"name":124,"@type":111,"acceptedAnswer":125},"What cell death mechanism is observed after treatment?",{"text":126,"@type":114},"Cell cycle analysis indicates apoptotic cell death is induced in the G1/S phase by the drug delivered through the chitosomal system.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},351851,1790420733,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nFormulation, characterization and evaluation of cytotoxic potential for febuxostat loaded chitosomes against cervical cancer cells (Hela cells)  \nWedad Sakran, Mai Abdel‑Hakim & Rania S. Abdel‑Rashid  \nThe presented study is focused on evaluating the efficiency of repurposing Febuxostat (FBX)  \nas a chemotherapeutic newcomer against the cervical cancer cell line (Hela cells) . Exploiting nanotechnology benefits in drug delivery, FBX was incorporated into chitosan‑coated niosomes (Chitosomes). Using a 23 factorial design, eight formulations were characterized for their entrapment efficiency percentage, particle size, and zeta potential. The optimum (FBX) loaded chitosomes displayed a mean particle size of 339 ± 14 nm, an entrapment efficiency of 91.07 ± 0.33%, and a Zeta potential of + 26.9 ± 1.2 ± 1.2 mV. In vitro cytotoxicity studies performed on Hela cells indicated a significant (P \u003C 0.05) decrease in IC50 value around 3‑fold compared with pure FBX. The cellular uptake showed a 2‑fold increase compared to the free drug. Upon studying the cell death cycle, it was revealed that apoptotic cell death was caused by the drug in the G1/S phase. Altogether, these findings revealed that the optimized chitosomal dispersion exhibited superior cytotoxic activity compared to free FBX, indicating it as a promising efficient and biocompatible delivery system for cervical cancer treatment.  \nKeywords Chitosomes, Repurposing, Cervical cancer, Febuxostat, Hela cells  \nCervical cancer is considered the fourth cause of death from cancer in women and comes in the second place as the most prevalent cancer among gynecologic cancers after breast cancer1. The traditional applied treatments are surgery, radiotherapy, or radio-chemotherapy. As well as being expensive, these treatments harmfully impact the quality of women’s lives by producing several side effects, like hair loss, immunosuppression, nausea, and frequently have a life-threatening prognosis2. Febuxostat (FBX) is an FDA-recognized medication for gout with a proven safety record designed to lower uric acid levels. FBX exists in numerous pharmaceutical dosage forms including emulsions, solid dispersion, and tablets for treatment of hyperuricaemia3–5. Recently, it was reported that FBX may act as a protective agent against tumor lysis syndrome in patients with malignant tumors treated by chemotherapy6. Moreover, FBX showed cytotoxic actions in various tumor cell lines as A549 non-small cell lung cancer7, and HCT116 human colorectal carcinoma inducing apoptotic effects mediated by caspase 38.  \nThough, many cytotoxic agents when administered in their free form are impeded by poor water solubility, limited bioavailability, rapid metabolic degradation and non-specific distribution, all of which significantly decrease their therapeutic efficacy and raise the risk of adverse effects9, 10.  \nNanotechnology has emerged as a transformative platform in cancer diagnosis and treatment, donating advanced strategies to improve drug solubility, targeting, and therapeutic efficacy. As highlighted in pervious review nanoparticle-based systems can enhance the pharmacokinetic profile of chemotherapeutic agents, enable controlled drug release, and improve tumor accumulation through both passive and active targeting mechanisms. Within this broad class of cancer nanotherapeutics, vesicular systems such as niosomes and liposomes have gained considerable attention due to their biocompatibility and ability to encapsulate hydrophobic drugs. Surface modification of these carriers further refines their performance. In this context, coating with chitosan represents a promising strategy to enhance mucoadhesion, cellular interaction, and localized drug delivery11.  \nPharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Capital University, Ain Helwan, Cairo 11795, Egypt. [email: Mai.Abdelhakim@pharm.capu.edu.eg](email: Mai.Ab","cbCaiqDtei2Z8SO8","https://ap.wps.com/l/cbCaiqDtei2Z8SO8","pdf",5278529,18,"English","# Background and Rationale\n# Nanotechnology and Niosomes\n## Chitosan coating and chitosan properties\n# Study Design and Formulation Strategy\n# Physicochemical Characterization\n# In Vitro Cytotoxicity and Cellular Uptake\n# Cell Death Cycle Mechanism\n# Conclusions","[{\"question\":\"How are febuxostat-loaded chitosomes prepared and optimized?\",\"answer\":\"FBX is incorporated into chitosan-coated niosomes (chitosomes). A 23 factorial design evaluates multiple formulations based on entrapment efficiency, particle size, and zeta potential to identify an optimized dispersion.\"},{\"question\":\"What physicochemical results are reported for the optimum formulation?\",\"answer\":\"The optimized FBX-loaded chitosomes show a mean particle size of 339 ± 14 nm, entrapment efficiency of 91.07 ± 0.33%, and a zeta potential around +26.9 ± 1.2 mV.\"},{\"question\":\"How does the formulation affect cytotoxicity against Hela cells compared with free FBX?\",\"answer\":\"In vitro studies show a significant ~3-fold decrease in IC50 compared with pure FBX, and cellular uptake increases about 2-fold relative to the free drug.\"},{\"question\":\"What cell death mechanism is observed after treatment?\",\"answer\":\"Cell cycle analysis indicates apoptotic cell death is induced in the G1/S phase by the drug delivered through the chitosomal system.\"}]","Formulation, characterization and evaluation of cytotoxic potential for febuxostat loaded chitosomes against cervical cancer cells (Hela cells) | PDF",1790096305,45,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e472d6605e5a8ef5370dad75171711c.webp",983,1291,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e925837f83d95a0fda01271e98d5bf73.webp",982,1290,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebdb2ea509d84cbe355c245670ebfcf3.webp",981,1289,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a9f19efe224a997335c410af44fcd10.webp",980,1287]